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ABSTRACT
 
Aim
 
To study the role of  cannabis use in the onset of  symptoms and disorders
in the schizophrenia spectrum.
 
Design
 
Review of  five population-based, longitudinal studies on the relation-
ship between cannabis use and problems ranging from the experience of
psychotic symptoms to hospitalization with a confirmed diagnosis of  schizo-
phrenia. Several hypotheses are examined that may explain this relationship:
(1) self-medication; (2) effects of  other drugs; (3) confounding; (4) stronger
effect in predisposed people, and (5) etiological hypothesis.
 
Findings
 
Hypotheses 1 and 2 can be dismissed; hypothesis 3 is still open to
debate, and converging evidence is found for hypotheses 4 and 5—antecedent
cannabis use appears to act as a risk factor in the onset of  schizophrenia, espe-
cially in vulnerable people, but also in people without prior history.
 
Conclusion
 
There is an intrinsic message here for public health, but how that
message is to be translated into action is not immediately clear.
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INTRODUCTION
 
It has been known for some time that there is a relation-
ship between cannabis use and schizophrenia (Thorni-
croft 1990; Heeler, Dingemans & Linszen 1992).
However, the precise nature of  this relationship remained
unclear: previous reviews were based mainly on cross-
sectional or clinical studies. In these studies, the temporal
sequence of  cannabis use and schizophrenia could not be
established, and it was difficult to disentangle effects of
confounding, selection bias and the effects of  other drugs
(Degenhardt 2003). Consequently, the etiological status
of  cannabis use in the pathogenesis of  schizophrenia
remained the subject of  a somewhat uninformed debate
(Johns 2001; Hanak 
 
et al
 
. 2002; Murray 
 
et al
 
. 2003).
Recently, five large-scale longitudinal studies
appeared in Sweden (Zammit 
 
et al
 
. 2002), Israel (Weiser
 
et al
 
. 2002), New Zealand (two studies: Arseneault 
 
et al
 
.
2002; Fergusson, Horwood & Swain-Campbell 2003)
and the Netherlands (Van Os 
 
et al
 
. 2002). These studies
shed new light on the relationship between cannabis use
and schizophrenia. Where insufficient proof  used to
hamper a meaningful discussion about the etiological
nature of  the relationship, now converging evidence has
emerged indicating that cannabis use does indeed act as a
risk factor in the onset of  schizophrenia.
It is worth noting that in this debate the term ‘schizo-
phrenia’ is used as a catchword referring to a broad range
of  psychotic conditions. At one extreme it denotes the
self-reported presence of  psychotic symptoms (one study)
and at the other extreme it means nothing less than hos-
pitalization with a confirmed diagnosis of  schizophrenia
(two studies). Between these extremes are studies that
have as outcomes the diagnoses of  psychotic and schizo-
phreniform disorder. Thus, the outcome that interests us
here is better described as a continuum of  psychotic
symptoms and full-blown disorders in the schizophrenia
spectrum. However, following common usage, ‘schizo-
phrenia’ will be used as a generic name throughout this
paper, unless more precise descriptions can be offered. We
will return to this issue later.
Two other issues need also be mentioned here. This
paper is restricted to the relationship between cannabis
use and schizophrenia, but it should be noted that other
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mental disorders, like depressive disorder, are the subject
of  a similar debate (Patton 
 
et al
 
. 2002). Furthermore, we
will not address the immediate psychotic reactions—such
as hallucinations—that can be induced by heavy can-
nabis use. These are often seen as acute, toxic and usually
transient reactions. In contrast to these immediate and
temporary reactions, we will focus on the (often by several
years) later onset of  long-lasting schizophrenia. There-
fore, the distinguishing features are the much greater
time lag and the far more persistent, if  not chronic, nature
of  the condition that will be discussed in this paper.
We will take the competing hypotheses that are cus-
tomarily put forward to explain the relationship between
cannabis use and schizophrenia as a starting point for
this study. Next, we will describe how the recent studies
tested the hypotheses. Finally, we will address the infer-
ences that can be made and the implications they have for
public mental health.
 
METHODS
 
Hypotheses
 
There are five hypotheses about the relationship between
cannabis use and schizophrenia:
 
1
 
The self-medication hypothesis
 
. Schizophrenia causes
cannabis use because those already suffering from
schizophrenia, or its symptoms, use cannabis in an
attempt to cope with the negative symptoms (depressed
or blunted affect) that stem from schizophrenia. People
may also use cannabis in an attempt to suppress the
side-effects of  antipsychotic medication. The self-
medication hypothesis thus implies a reversed
causality.
 
2
 
Other drugs hypothesis
 
. Cannabis use is often accompa-
nied by the use of  other drugs like amphetamines,
opiates and cocaine, and it is not cannabis but the
other drugs that are responsible for the later onset of
schizophrenia.
 
3
 
Confounding hypothesis
 
. Both cannabis use and schizo-
phrenia are brought about by one or more common
etiological factors. The relationship between cannabis
use and schizophrenia thus is spurious.
 
4
 
Interaction hypothesis
 
. Cannabis use may cause schizo-
phrenia, but only in persons already at risk of  becom-
ing schizophrenic. In other words, these persons are in
some way vulnerable (genetically or otherwise) and
cannabis use only triggers the onset of  schizophrenia.
 
5
 
Etiological hypothesis
 
. Cannabis use makes its own
(unique) contribution to the risk of  becoming
schizophrenic.
An etiological claim, such as in hypotheses 1, 4 and 5,
can be made—within reasonable bounds—when the
following criteria are met (Rothman & Greenland 1998):
(1) there is a probabilistic association between an 
 
x
 
-vari-
able (the assumed ‘cause’) and a 
 
y
 
-variable (the ‘effect’);
(2) 
 
x
 
 precedes 
 
y
 
 in time, and (3) the influence of  a con-
founder, 
 
z
 
, that causes both 
 
x
 
 and 
 
y
 
 can be ruled out. An
etiological claim can be further strengthened when a
dose–response relationship can be found. Therefore, in
people who used more cannabis, a proportionally greater
risk of  becoming schizophrenic must be observed. Later in
this paper  we  describe  how,  in  the  new  studies,  atten-
tion was paid to the temporal sequence, confounding and
dose–response.
 
Subjects, procedures and measures in the new studies
 
The Swedish study (Zammit 
 
et al
 
. 2002) is a follow-up of
a previously published historical cohort study of  50 087
military conscripts who were 18–20 years old in 1969–
1970 (Andreasson 
 
et al
 
. 1987). All conscripts received a
medical examination and had to answer a questionnaire
on drug use, including the use of  cannabis. The con-
scripts were further examined by a psychologist and, if
they presented symptoms of  a mental disorder, also by a
psychiatrist. At that time, 34 conscripts met the diagnos-
tic criteria of  the International Classification of  Disorders
(ICD) of  a psychosis. They were excluded from the study.
In the next step, 362 persons were identified who were
hospitalized with an ICD diagnosis of  schizophrenia or
(paranoid) psychosis in the period 1970–1996 and of
whom the military medical records could be traced. In
this way, the relationship between previous cannabis use
and later onset of  schizophrenia could be established.
The study from Israel (Weiser 
 
et al
 
. 2002) was con-
ducted along similar lines. In the 1980s and 1990s,
50 413 conscripts who presented symptoms of  behav-
ioural or conduct disorders had to answer a question-
naire on drug use. Their medical records were later
combined with data from the National Psychiatric Case
Register. In all, 509 persons were identified who were
hospitalized with a ICD-9 diagnosis of  schizophrenia 4–
15 years after their military service medical examina-
tion. For data analytical purposes, these cases were com-
pared with 9215 former classmates who acted as
‘healthy’ controls.
The first study from New Zealand (Arseneault 
 
et al
 
.
2002) was based on a birth cohort of  1037 people born
in 1972–1973. When they had reached the age of  11,
they were examined to see if  they presented self-reported
psychotic symptoms. At 15–18 years, the same proce-
dure was followed to see if  the subjects used cannabis. At
the age of  26, they received a standardized diagnostic
interview to see if  they met the diagnostic criteria of
schizophreniform disorder according the fourth version
of  the Diagnostic Statistical Manual (DSM-IV). At that
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measurement, 96% of  the birth cohort still participated
in the study.
The second study from New Zealand (Fergusson 
 
et al
 
.
2003) is another birth cohort with measurements on an
annual basis until the cohort had reached the age of  16.
Additional measures were taken at age 18. It was then
ascertained whether the 1025 18-year-olds met the
DSM-IV diagnostic criteria of  cannabis dependency and
whether psychotic symptoms were manifest. This was
repeated at age 21, when 1011 people still participated in
the study. Psychotic symptomatology was measured with
the 10 psychosis items of  the Symptom Checklist 90 (SCL-
90). The corresponding scale had a reliability of  0.73
(Cronbach’s alpha). When studying the relationship
between cannabis use and schizophrenia, the researchers
corrected for confounders (among them antecedent
mental problems and social, family and personality
characteristics).
The study that was conducted in the Netherlands (Van
Os 
 
et al
 
. 2002) was based on the data of  the Netherlands
Mental Health Survey and Incidence Study: Nemesis (Bijl,
Van Zessen & Ravelli 1998). This is a population-based
cohort study among 7076 adults aged 18–65 years.
Three measurement waves were carried out, in 1996,
1997 and 1999. In the last wave, 4848 people were
retained. In the analyses, the possible effect of  loss-to-
follow-up was studied with the help of  sensitivity
analyses. DSM-III-R diagnoses (American Psychiatric
Association 1987) were ascertained in all three waves
with the help of  structured, computer-assisted, face-to-
face interviews, using the Composite International Diag-
nostic Instrument (CIDI) (Smeets & Dingemans 1993).
Respondents who scored positive on psychotic symptoms
received a structured clinical re-examination by tele-
phone. The results of  both the CIDI interview and this
re-examination were discussed systematically with two
psychologists and two psychiatrists in order to reach con-
sensus on the clinical status. The study was restricted to
the 4045 people who had no prior history with symptoms
of  psychosis as established in the baseline measurement.
Table 1 lists characteristics of  the studies and reports
on their results. Table 2 lists how each of  the studies dealt
with the alternative hypotheses.
 
RESULTS
 
Which hypotheses can now be eliminated?
 
The self-medication hypothesis can probably be elimi-
nated as a valid explanation for the relationship between
cannabis use and the onset of  schizophrenia. The studies
under consideration employed several strategies to test
the self-medication hypothesis. All studies looked into the
temporal sequence and were interested to see what came
first: cannabis use followed by schizophrenia, or the other
 
Table 1
 
Design, measures and outcomes of the reviewed studies.
 
Country Study Sample size Design Follow-up time
Definition of
cannabis use Definition of outcome Effect size
 
Sweden Zammit 
 
et al
 
. 
(2002)
 
n
 
 
 
=
 
 50.053 Historical 
cohort 
study
11–14 years Life-time cannabis 
use, frequency of 
use
Hospitalization with 
ICD-8/9 
schizophrenia or 
paranoid 
psychosis
OR 
 
=
 
 2.1–2.5
 
a
 
Israel Weiser 
 
et al
 
. 
(2002)
 
n
 
 
 
=
 
 9.724 Historical 
cohort 
study
4–15 years Life-time 
cannabis use,
 
b
 
frequency of use
Hospitalization with 
ICD-9 
schizophrenia
OR 
 
=
 
 2.0
New Zealand Arseneault 
 
et al
 
. (2002)
 
n
 
 
 
=
 
 1.253 Birth cohort 15 years Cannabis use 
 
≥ 
 
3 
times
DSM-IV 
schizophreniform 
disorder
OR 
 
=
 
 11.4
 
c
 
New Zealand Fergusson 
 
et al
 
. (2003)
 
n
 
 
 
=
 
 1.011 Birth cohort 3 years CIDI/DSM cannabis 
dependency
Number of psychotic 
SCL-90 symptoms
IRR 
 
=
 
 1.8
Netherlands Van Os 
 
et al
 
.
(2002)
 
n
 
 
 
=
 
 4.045 Cohort 
study
3 years Life-time cannabis 
use, frequency of 
use
 
d
 
CIDI/DSM-III-R 
schizophrenia and 
other psychotic 
disorders
 
e
 
OR 
 
=
 
 3.5–3.7
 
f
 
a
 
Depending on the frequency of cannabis use: 11–50 times and 
 
>
 
50 times; 
 
b
 
mainly cannabis use; 
 
c
 
among those who used cannabis before age 15; 
 
d
 
less than once
per month, 1–3 days per month, 1–2 days per week, 3–4 days per week, every day; 
 
e
 
confirmed by a clinical re-examination using the Structured Clinical Interview
(SCID), three items from the Brief Psychiatric Rating Scale (BPRS) and a consensus meeting attended by two psychologists and two psychiatrists using the
Camberwell Assessment of Needs (CAN); 
 
f
 
depending on the pathology level in the outcome.
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way round. Some studies employed the strategy to con-
duct analysis on the subgroup that had no prior history of
schizophrenia or symptoms thereof. Table 2 shows which
strategy was followed for each study. For example, in the
Swedish study 34 conscripts were excluded from the
study because they showed signs of  a psychotic disorder
at the time of  recruitment. In addition, a subgroup ana-
lysis was conducted in the group that developed schizo-
phrenia only 5 years after conscription. In this way,
subjects were excluded who might have used cannabis
because they suffered from (prodromal symptoms of)
schizophrenia. The study from the Netherlands was
conducted exclusively on the 4045 people who had no
history—on a lifetime basis—of  psychotic symptoms. The
same strategy was followed in the study from Israel, while
both studies from New Zealand used statistical tech-
niques to control for any prior history with symptoms of
any mental disorder. In all these analyses, the results indi-
cated that the later onset of  symptoms and disorders in
the schizophrenia spectrum was preceded by prior use of
cannabis. This finding does not imply that people suffer-
ing from schizophrenia do not use cannabis as some form
of  ‘self-medication’, but these results do imply that can-
nabis use increases the risk of  later schizophrenia even
when self-medication can be ruled out as an explanation.
The other drugs hypothesis can be eliminated. It is
true that cannabis users often use other drugs (Smit,
Monshouwer & Verdurmen 2002), but multivariate anal-
ysis, in which the effects of  other drugs are also evalu-
ated, indicates that it is not the other drugs, but only
cannabis that makes its own (unique) contribution to the
risk of  becoming schizophrenic. All studies, with the
exception of  the one from Israel, controlled for the influ-
ence of  other substances. After controlling, the effect of
cannabis use remained.
 
Which hypotheses are still uncertain?
 
The confounding hypothesis still leaves room for further
debate. Both the Swedish and the Dutch study try, as far as
possible, to control for confounding. The strength of  the
relationship between cannabis use and schizophrenia
[expressed in odds ratios, (ORs)] becomes less and less
when adjusted for more confounders. In the Swedish
study, the ORs decrease by 30% after correction; in the
Dutch study, ORs decrease by 20%. It is of  note that in
both studies the corrections were carried out for different
sets of  confounders, suggesting that the ORs will be
reduced to half  their original, unadjusted, values when
corrected for all confounders—not to mention unob-
 
Table 2
 
Elimination of the alternative hypotheses in the reviewed studies.
 
Study
Eliminated effect of prior
history of psychosis?
Eliminated the
effect of
other
substances?
Eliminated the effect
of confounders?
Studied
interaction
effect?
Found support for a 
dose–response
relationship?
 
Zammit 
 
et al
 
. (2002) Yes, found temporal 
sequence and 
conducted analysis in 
psychosis-free group
Yes Yes: IQ, social network, 
urbanicity
Not studied Yes, larger risk of 
more cannabis use
Weiser 
 
et al
 
. (2002) Yes, found temporal 
sequence and 
conducted  analysis in 
psychosis-free group
No Yes, but confounders were 
not described
Not studied Not studied
Arseneault 
 
et al
 
. (2002) Yes, found temporal 
sequence and adjusted 
statistically for history
Yes No Not studied Not studied
Fergusson 
 
et al
 
. (2003) Yes, found temporal 
sequence and adjusted 
statistically for history
Yes Yes
 
a
 
Not studied Not studied
Van Os 
 
et al
 
. (2002) Yes, found temporal 
sequence and 
conducted analysis in 
psychosis-free group
Yes Yes: gender, age, ethnic 
descent, marital status, 
education, employment, 
urbanicity, experiences 
with discrimination
Yes, and this 
implies  an 
etiological 
role of  
cannabis 
use
Yes, larger risk of 
more cannabis use
 
a
 
Confounders in the study of Fergusson 
 
et al
 
. (2003): family (age of parents, educational level of parents, SES of parents); familial functioning (divorce, parental
conflicts, life events, parental bonding, child abuse); parental adjustment (mental health, problem drinking, crime, illicit drug use); child (gender, neuroticism,
sensation-seeking, IQ, educational attainment); medical history until age 16 (substance use and misuse and mental disorders, including anxiety and mood
disorders).
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served confounders. The largest number of  confounders
were accounted for in the second study from New Zealand
(see Table 2). After controlling, the effect [expressed in an
incidence rate ratio (IRR), comparable with the OR]
equals 1.8, while the unadjusted IRR was 2.3.
 
Which hypotheses find support?
 
The interaction hypothesis has now received a better
empirical basis in the Dutch study. This study shows that
vulnerable people (with a history of  psychosis) have a
much greater risk of  schizophrenia than cannabis users
without a history. The risk difference (RD) of  using or not
using cannabis is 2.2% for those without a history of  psy-
chosis, whereas RD 
 
=
 
 54.7% in those with a history, and
the underlying interaction effect was significant at
 
P
 
 
 
<
 
 0.001 (Van Os 
 
et al
 
. 2002). It is worth noting that the
interaction hypothesis implies an etiological role of  can-
nabis use in the onset of  schizophrenia.
Finally, the etiological hypothesis has become more
plausible through: (1) the elimination of  the self-
medication hypothesis; (2) the elimination of  the other
drugs hypothesis, and (3) support for the dose–response
relationship, in which those who used more cannabis in
the past will incur a proportionally greater risk of  experi-
encing the later onset of  schizophrenia, as has become
clear in the Swedish and Dutch studies. In the Swedish
study, it was shown that for people who used cannabis
fewer than 50 times, the risk of  becoming schizophrenic
doubled, but for those using cannabis more frequently
the OR was between 2.1 and 21.7, after adjusting for con-
founders (Zammit 
 
et al
 
. 2002). A similar dose–response
effect is reported in the Dutch study (Van Os 
 
et al
 
. 2002).
 
DISCUSSION
 
This review aimed to answer the question of  whether
cannabis use increases the risk to develop symptoms and
disorders in the schizophrenia spectrum. The results may
now be summarized as follows. Five recent, longitudinal
and carefully executed studies offer converging evidence
that cannabis use does indeed increase the risk of  schizo-
phrenia and other psychotic disorders. This conclusion
applies throughout the range of  symptoms and full-
blown disorders in the schizophrenia spectrum.
It is of  note that alternative explanations (self-
medication, use of  other substances, effect of  confound-
ers) could be eliminated for the better part. This leaves
ample room for the two remaining hypotheses: (1) can-
nabis use increases the risk but particularly in vulnera-
ble people, and (2) cannabis use makes its own unique
contribution to the risk of  becoming schizophrenic. Both
hypotheses find support, and both hypotheses imply an
etiological role of  cannabis use in the pathogenesis of
schizophrenia.
Some caution is required here. Epidemiological cohort
studies do not lend themselves very well to proof  that can-
nabis use will increase, in an etiological way, the risk of
becoming schizophrenic. After all, the etiological claim
can always be challenged by (unobserved) confounders,
and it is too early to dismiss the confounding hypothesis.
Furthermore, it is difficult to obtain accurate assessments
of  cannabis consumption and therefore the dose–
response concept is also somewhat problematic. A plau-
sible etiological theory, preferably underpinned by bio-
medical research on the effects of  cannabinoids on the
neurotransmitter systems, would be helpful here.
How large is the risk? With five new cases per 10 000
person years, the incidence rate of  schizophrenia is small
(Bijl 
 
et al
 
. 2002). Assuming a causal mechanism, this risk
will become larger—roughly by a factor 2—in cannabis
users (see Table 1). The risk rate will then still be small,
but its clinical consequences are to be taken seriously.
What can be said about the exposure to the risk? In the
member states of  the European Union and in the USA,
17.6% of  16-year-olds have used cannabis (Hibell 
 
et al
 
.
2000). Thus even in this young age group the exposure
rate is substantial.
The interaction hypothesis implies that vulnerable
cannabis users have a much higher risk of  becoming
schizophrenic than others who are not vulnerable, but
when would we describe a person as being vulnerable?
There is little doubt about someone’s vulnerability where
there is a history of  psychosis (Van Os 
 
et al
 
. 2002), but this
is obviously a small group and few people will regard
themselves as vulnerable in this sense. However, the psy-
chotic phenotype does not only express itself  in its most
extreme form—schizophrenia—but can also manifest
itself  in a single psychotic symptom. This is a fairly com-
mon experience with a prevalence of  17.5% in the general
population (Van Os 
 
et al
 
. 2000). The concept of  vulnera-
bility can have an even broader definition. On an annual
basis, almost a quarter of  the general population meets the
diagnostic criteria of  one or another DSM axis-I diagnosis
(Bijl, Ravelli & Van Zessen 1998), and this tells us some-
thing about the distribution of  vulnerability in the popu-
lation. Thus, vulnerability can be defined in a more
narrow or a more broad way, but it should be noted that
the broader definitions have not been tested in the
reviewed studies. The debate on cannabis use and later
schizophrenia could therefore benefit from studies in
which dose–response effects are studied across a broad
range of  vulnerability levels.
All in all, we conclude that the reviewed studies are
the bearers of  a message that contains six key elements:
 
1
 
Cannabis use roughly doubles the risk of  becoming
schizophrenic.
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2
 
Many young people expose themselves to this risk.
 
3
 
The risk gets larger when more cannabis is used.
 
4
 
The risk also becomes larger in ‘vulnerable’ people.
 
5
 
Vulnerability may be a widespread, but difficult to rec-
ognize characteristic.
 
6
 
Even when the risk is numerically small, in clinical
terms it is serious.
This is the message. However, it will require wisdom to
formulate a health educational message that will gener-
ate a desirable effect. Warnings may not help and may
even be counter-productive, but ignoring the message of
the five studies is not an option.
 
ACKNOWLEDGEMENTS
 
This paper was previously published in 
 
The Netherlands
Journal of  Medicine
 
 [
 
Nederlands Tijdschrift voor Geneeskunde
 
(
 
NTvG
 
)]. The authors are grateful for the kind permission
of  the editorial board of  
 
NTvG
 
 to let us use the original
article for this reworked version.
 
REFERENCES
 
American Psychiatric Association (1987) 
 
Diagnostic and Statis-
tical Manual of  Mental Disorders: DSM-III-R
 
 (3rd revised edn).
Washington, DC: American Psychiatric Association.
Andreasson, S., Allebeck, P., Engstrom, A. & Rydberg, U. (1987)
Cannabis and schizophrenia: a longitudinal study of  Swedish
conscripts. 
 
Lancet
 
, 
 
2
 
, 1483–1486.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A. &
Moffitt, T. E. (2002) Cannabis use in adolescence and risk for
adult psychosis: longitudinal prospective study. 
 
BMJ
 
, 
 
325
 
,
1212–1213.
Bijl, R. V., De Graaf, R., Ravelli, A., Smit, F. & Vollebergh, W. A.
M. (2002) Gender and age-specific first incidence of  DSM-III-R
psychiatric disorders in the general population: results from
the Netherlands Mental Health Survey and Incidence Study
(NEMESIS). 
 
Social Psychiatry and Psychiatric Epidemiology
 
, 
 
37
 
,
372–379.
Bijl, R. V., Ravelli, A. & Van Zessen, G. (1998) Prevalence of  psy-
chiatric disorder in the general population: results of  the Neth-
erlands Mental Health Survey and Incidence Study
(NEMESIS). 
 
Social Psychiatry and Psychiatric Epidemiology
 
, 
 
33
 
,
587–595.
Bijl, R. V., Van Zessen, G. & Ravelli, A. (1998) The Netherlands
Mental Health Survey and Incidence Study (NEMESIS): objec-
tives and design. 
 
Social Psychiatry and Psychiatric Epidemiol-
ogy
 
, 
 
33
 
, 581–586.
Degenhardt, L. (2003) The link between cannabis use and psy-
chosis: furthering the debate. 
 
Psychological Medicine
 
, 
 
33
 
, 3–6.
Fergusson, D. M., Horwood, L. J. & Swain-Campbell, N. R.
(2003) Cannabis dependence and psychotic symptoms in
young people. 
 
Psychological Medicine
 
, 
 
33
 
, 15–21.
Hanak, C., Tecco, J., Verbanck, P. & Pelc, I. (2002) Cannabis,
mental health and dependence. In: Spruit, I., ed. 
 
Cannabis
2002 Report
 
, pp. 63–69. Brussels: Ministry of  Public
Health.
Heeler, H., Dingemans, P. & Linszen, D. (1992) Cannabis en
schizofrenie: een literatuuronderzoek [Cannabis and schizo-
phrenia: a review]. 
 
Tijdschrift Voor Psychiatrie
 
, 
 
34
 
, 699–
708.
Hibell, B., Andersson, B., Ahlström, S., Balakireva, O., Bjarnas-
son, T., Kokkevi, A. & Moran, M. (2000) 
 
The 1999 ESPAD
Report: Alcohol and Other Drugs in 30 European Countries.
 
Stockholm: Modin Tryck.
Johns, A. (2001) Psychiatric effects of  cannabis. 
 
British Journal of
Psychiatry
 
, 
 
178
 
, 116–122.
Murray, R. M., Grech, A., Phillips, P. & Johnson, S. (2003) What
is the relationship between substance abuse and schizophre-
nia? In: Murray, R. M., Jones, P. B., Susser, E., van Os, J. &
Cannon, M., eds. 
 
The Epidemiology of  Schizophrenia
 
, pp. 317–
342. Cambridge: Cambridge University Press.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M.
& Hall, W. (2002) Cannabis use and mental health in young
people: cohort study. 
 
BMJ
 
, 
 
325
 
, 1195–1198.
Rothman, K. J. & Greenland, S. (1998) 
 
Modern Epidemiology
(2nd edn). Philadelphia, PA: Lippincott-Raven.
Smeets, R. M. W. & Dingemans, P. M. A. J. (1993) Composite
International Diagnostic Interview (CIDI), Version 1.1. Geneva:
World Health Organization.
Smit, F., Monshouwer, K. & Verdurmen, J. (2002) Polydrug use
among secondary school students: combinations, prevalences
and risk profiles. Drugs: Education, Prevention and Policy, 9,
355–365.
Thornicroft, G. (1990) Cannabis and psychosis: is there epide-
miological evidence for an association? British Journal of  Psy-
chiatry, 157, 25–33.
Van Os, J., Bak, M., Hanssen, M., Bijl, R. V., De Graaf, R. & Ver-
doux, H. (2002) Cannabis use and psychosis: a longitudinal
population-based study. American Journal of  Epidemiology,
156, 19–27.
Van Os, J., Hanssen, M., Bijl, R. V. & Ravelli, A. (2000) Strauss
(1969) revisited: a psychosis continuum in the general popu-
lation? Schizophrenia Research, 45, 11–20.
Weiser, M., Knobler, H. Y., Noy, S. & Kaplan, Z. (2002) Clini-
cal characteristics of  adolescents later hospitalized for
schizophrenia. American Journal of  Medical Genetics, 114,
949–955.
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. & Lewis,
G. (2002) Self-reported cannabis use as a risk factor for
schizophrenia in Swedish conscripts of  1969: historical
cohort study. BMJ, 325, 1199–1201.

